Evidence map›Paper›PMID 25123903›Full record

ArticleBioinformatics (Oxford, England)2014

HapMuC: somatic mutation calling using heterozygous germ line variants near candidate mutations.

Naoto Usuyama, Yuichi Shiraishi, Yusuke Sato, Haruki Kume, Yukio Homma, Seishi Ogawa, Satoru Miyano, Seiya Imoto

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Somatic and Germline Variant Calling from Next-Generation Sequencing Data.Advances in experimental medicine and biology · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naoto UsuyamaHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Yuichi ShiraishiHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Yusuke SatoHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Haruki KumeHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Yukio HommaHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Seishi OgawaHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Satoru MiyanoHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Seiya ImotoHuman Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655 and Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationIdentifying somatic changes from tumor and matched normal sequences has become a standard approach in cancer research. More specifically, this requires accurate detection of somatic point mutations with low allele frequencies in impure and heterogeneous cancer samples. Although haplotype phasing information derived by using heterozygous germ line variants near candidate mutations would improve accuracy, no somatic mutation caller that uses such information is currently available.

resultsWe propose a Bayesian hierarchical method, termed HapMuC, in which power is increased by using available information on heterozygous germ line variants located near candidate mutations. We first constructed two generative models (the mutation model and the error model). In the generative models, we prepared candidate haplotypes, considering a heterozygous germ line variant if available, and the observed reads were realigned to the haplotypes. We then inferred the haplotype frequencies and computed the marginal likelihoods using a variational Bayesian algorithm. Finally, we derived a Bayes factor for evaluating the possibility of the existence of somatic mutations. We also demonstrated that our algorithm has superior specificity and sensitivity compared with existing methods, as determined based on a simulation, the TCGA Mutation Calling Benchmark 4 datasets and data from the COLO-829 cell line. AVAILABILITY AND IMPLEMENTATION: The HapMuC source code is available from http://github.com/usuyama/hapmuc.

Indexed as

HeterozygoteAlgorithmsBayes TheoremCell Line, TumorDNA Mutational AnalysisGene FrequencyHaplotypesHumansMutationNeoplasmsPolymorphism, Single Nucleotide

Identifiers

PMID25123903
PMCPMC4816033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.